Form 4: Director Dawn Halkuff Executes Stock Transactions at XERS

Director Dawn Halkuff of Xeris Biopharma Holdings, Inc. reported a sale of 20,000 shares and an acquisition of equity awards.

Summary

• Director Dawn Halkuff sold 20,000 shares of common stock at a weighted average price of $6.0943 per share.
• The sale was conducted under a pre-established Rule 10b5-1 trading plan adopted on September 4, 2025.
• The director was granted 24,193 restricted stock units (RSUs) and 32,996 stock options with an exercise price of $6.15.
• Following these transactions, the director holds 119,193 shares directly and 5,410 shares indirectly via a revocable trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and offset by the receipt of new equity compensation.

Positives

• The director continues to maintain a significant equity stake in the company, totaling 124,603 shares combined.
• The acquisition of new equity awards aligns the director's interests with long-term shareholder value.

Negatives

• The director liquidated 20,000 shares, which may be perceived as a reduction in direct exposure to the company's stock performance.

Risks

• The stock options and RSUs are subject to continued service requirements through the vesting date of June 4, 2026.

Future Outlook

The equity awards granted to the director are scheduled to vest on June 4, 2026, or upon the date of the next annual meeting of stockholders, whichever occurs first.

Industry Context

StockSavvy.ai notes that insider sales conducted via Rule 10b5-1 plans are standard corporate governance practices used to provide liquidity while avoiding concerns regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard industry practice for executives and directors to manage personal portfolios.
• Equity grants to directors are consistent with standard compensation packages for mid-cap biopharmaceutical companies.

Stakeholder Impact

• Shareholders should view the sale as a routine portfolio management action by the director rather than a signal of company performance.

Next Steps

• Vesting of 24,193 RSUs on June 4, 2026.
• Vesting of 32,996 stock options on June 4, 2026.

Key Dates

Keywords

Xeris Biopharma, XERS, Insider Trading, Form 4, Director Transactions, Equity Compensation